Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening
Authors:
- Nicolas TournierNTNicolas Tournier
- Héric ValetteHVHéric Valette
- Marie-Anne PeyronneauMPMarie-Anne Peyronneau
- Wadad SabaWSWadad Saba
- Sébastien GoutalSGSébastien Goutal
- Bertrand KuhnastBKBertrand Kuhnast
- Frédéric DolléFDFrédéric Dollé
- Jean-Michel ScherrmannJSJean-Michel Scherrmann
- Salvatore CisterninoSalvatore Cisternino
- Michel BottlaenderMBMichel Bottlaender
Open Access
- 14 February 2011
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (3) , 415-423
Abstract
Radiolabeled compounds used for brain imaging with PET must readily cross the blood-brain barrier (BBB) to reach their target. Efflux transporters at the BBB-P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP)-could limit their uptake by the brain. We developed and validated an in vitro model using MDCKII cells transfected with human multidrug resistance (MDR1) or BCRP genes and assessed the transport of selected PET ligands by the concentration equilibrium technique. The tested compounds included befloxatone, (R,S)-CGP-12177, clorgyline, R-(-)-deprenyl, diprenorphine, DPA-714, fallypride, flumazenil, 2-fluoro-A-85380, LBT-999, loperamide, p-MPPF, PE2I, Pittsburgh compound B (PIB), (R,S)-PK11195, raclopride, R-(+)-verapamil, and WAY-100635. The assays were performed using the nonradioactive form of each compound (ultraviolet high-performance liquid chromatography analysis) and, when available, the (18)F-labeled analogs (γ-counting). Befloxatone appeared to be transported solely by BCRP. Loperamide, verapamil, and diprenorphine were the only P-gp substrates. Other ligands were transported by neither P-gp nor BCRP. The present method can readily be used to screen new-compound transport by P-gp or BCRP, even before any radiolabeling. Compounds that were previously thought to be transported by P-gp in rodents, such as p-MPPF, WAY-100635, and flumazenil, cannot be considered substrates of human P-gp. The impact of BCRP and P-gp at the BBB on the transport of befloxatone and diprenorphine in vivo remains to be evaluated with PET.Keywords
This publication has 42 references indexed in Scilit:
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- PET radiotracers: crossing the blood–brain barrier and surviving metabolismTrends in Pharmacological Sciences, 2009
- Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo ApplicationsClinical Pharmacology & Therapeutics, 2009
- Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein TransportDrug Metabolism and Disposition, 2009
- Changes in dipole membrane potential at the mouse blood–brain barrier enhance the transport of99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2Journal of Neurochemistry, 2009
- ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependenceHuman Molecular Genetics, 2008
- Genetic Polymorphisms in the ABCB1 Gene and the Effects of Fentanyl in KoreansClinical Pharmacology & Therapeutics, 2006
- Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugsPharmacology & Therapeutics, 2006
- Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1Pharmaceutical Research, 2006